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INTRODUCTION:  Visually  isoattenuating  pancreatic  adenocarcinoma  is deﬁned  as  a  mass  not  directly  vis-
ible  on CT  and  recognizable  only  by  secondary  imaging  signs.  The  frequency  of isoattenuating  pancreatic
adenocarcinomas  at dynamic-enhanced  CT has  been  reported  to range  from  5.4%  to  14%.  Furthermore,  80%
of  the  visually  isoattenuating  pancreatic  adenocarcinomas  are  detectable  in  dynamic-enhanced  MRI.  Con-
sequently,  a pancreatic  adenocarcinoma  undetected  in both  the  above  imaging  studies  is  an  exceptionally
rare  event.
PRESENTATION  OF  CASE:  The  present  report  describes  a case  of  a histologically  proved  3.5 cm  pancreatic
adenocarcinoma  undetected  in  both  dynamic-enhanced  CT  and  MRI.  The  patient  presented  with  progres-
sive  jaundice  over  the  preceding  20 days.  Initial  abdominal  CT showed  a dilated  pancreatic  and  common
bile  duct  without  demonstration  of  a lesion  responsible  for the clinical  and  imaging  ﬁndings.  Additional
diagnostic  work-up  with  dynamic  CT  and  dynamic  MRI  failed  to reveal  a deﬁnitive  mass.  ERCP  revealed
an  irregular  interruption  of  the  pancreatic  and  distal  common  bile  duct  with  upstream  dilation.  Blind  rad-
ical  pancreaticoduodenectomy  was  performed.  Histologic  examination  showed  a pT3pN1MO  pancreatic
ductal  adenocarcinoma  of  the head/neck.
DISCUSSION: Isoattenuating  pancreatic  adenocarcinoma  patients  represent  a  small  but  meaningful  subset
of  patients  with  pancreatic  cancer,  as they  have  better  survival.  The  more  favorable  postsurgical  survival
makes  it  even  more  imperative  to correctly  diagnose  their  cases  at  early  stages  by  obtaining  further
diagnostic  work-up  with  dynamic  pancreatic  CT,  dynamic  MRI and  endoscopic  ultrasound.
CONCLUSION: When  the  above  studies  fail  to  unmask  the  lesion,  blind  pancreaticoduodenectomy  should
be  based  on  strong  clinical  suspicion  and  secondary  imaging  ﬁndings.
gical  © 2013 Sur
. Introduction
Multidetector row and dynamic dual-phase scanning have sub-
tantially improved the accuracy of CT for detection of pancreatic
ancer. However, some lesions, in which the tumor attenua-
ion is indistinguishable from the attenuation of the pancreatic
arenchyma, can still escape detection.1 The frequency of isoat-
enuating pancreatic adenocarcinomas at dynamic-enhanced CT
mong pathologically proved pancreatic cancers has been reported
o range from 5.4% to 14%.2 Furthermore, 80% of the visually
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isoattenuating pancreatic adenocarcinomas at CT are detectable in
dynamic-enhanced MRI.3 Consequently, a pancreatic adenocarci-
noma undetected in both dynamic CT and MRI is an exceptionally
rare event. Awareness and knowledge about this uncommon ﬁnd-
ing is important, as it could cause a missed or delayed diagnosis.
The present report describes a case of a histologically proved
isoattenuating pancreatic adenocarcinoma undetected in both
dynamic-enhanced CT and MRI.
2. Presentation of case
A 62-year-old male patient referred to our surgical department
owing to progressive jaundice associated with darkening of the
urine and pruritus over the preceding 20 days. Direct questioning
Open access under CC BY-NC-ND license.revealed a history of vague abdominal pain, anorexia and weight
loss of approximately 6 kg over the last 3 months, symptoms which
were attributed by the patient to exacerbation of peptic ulcer dis-
ease. There was  no other previous medical history. The patient was
Y-NC-ND license. 
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eig. 1. Transverse contrast-enhanced (a) arterial and (b) portal phase CT images
emonstrated  interruption of the pancreatic duct in the neck portion, as well as
pstream pancreatic duct dilatation. Images did not provide visualization of mass.
 smoker (15–20 cigarettes per day for the last 35 years) and an
ccasional alcohol drinker.
At initial presentation jaundice, palpable gallbladder and mus-
le wasting were present on physical examination. Laboratory
tudies revealed a signiﬁcant increase in serum total bilirubin
12.10 mg/dl), alkaline phosphatase (271 U/l) and -glutamyl trans-
erase (85 U/l). Serum amylase (40 U/l), IgG (982 mg/dl) and IgG4
56 mg/dl) levels were normal. Regarding tumor markers, level of
A 19-9 (60 U/ml) was elevated.
Transabdominal ultrasonography showed a dilated pancreatic
uct (5 mm),  dilated intrahepatic and extrahepatic bile ducts (com-
on  hepatic and bile duct ranged between 12.2 and 14.3 mm
n diameter) without gallstones and focal hepatic or pancre-
tic lesions. Initial abdominal CT demonstrated interruption of
ancreatic duct in the head/neck of pancreas with upstream pan-
reatic ductal dilation and biliary dilation, without any visible
ass or nodule. Diagnostic ERCP also performed and depicted
n irregular interruption of the pancreatic duct and narrowing
n the distal common bile duct with upstream dilation; a plas-
ic stent was placed across the biliary obstruction. Strong clinical
uspicion and secondary imaging signs for pancreatic head can-
er imposed additional diagnostic work-up. A dynamic-enhanced
ancreatic CT examination obtained with a 16-multidetector row
canner according to a dual-phase pancreatic protocol in order
o depict a deﬁnitive mass. However, no pancreatic lesion of
ncreased or decreased attenuation compared with the normal
ancreatic parenchyma was observed in both arterial and portal
hases (Fig. 1). Furthermore, gadolinium-enhanced dynamic MRI
xamination with nonenhanced fat-saturated T1-/T2-weightedFig. 2. Transverse (a) nonenhanced T2-weighted and (b) arterial phase contrast-
enhanced  T1-weighted MR images failed to expose the mass.
and contrast-enhanced arterial, venous and delayed phase fat-
saturated T1-weighted images obtained, in order to expose the
mass. Neither of these sequences achieved to demonstrate the
lesion (Fig. 2). No evidence of metastatic disease and invasion into
local structures was depicted.
Although preoperative imaging did not reveal a deﬁnitive mass,
resection of the presumed pancreatic carcinoma was decided 9 days
after presentation. The decision/making ﬂow chart of the study
patient is presented in Table 1.13 Radical pancreaticoduodenec-
tomy  was performed (standard resection plus distal gastrectomy
and retroperitoneal lymph node dissection extending from the
right renal hilum to the left lateral border of the aorta and from the
portal vein to the inferior mesenteric artery) with Roux-en-Y recon-
struction. In the surgical specimen the suspected mass appeared
inconspicuous and permeated into the pancreatic parenchyma
with indistinct margins and was recognizable only by its very
hard consistency on palpation at the neck of the pancreas. Histo-
logic examination showed a moderate differentiated, pT3pN1MO
and stage IIB according to the AJCC cancer staging manual, neg-
ative margin pancreatic ductal adenocarcinoma of the head/neck.
Postoperative course of the patient was uneventful and adjuvant
interferon-based chemoradiation was  performed.
3. DiscussionVisually isoattenuating pancreatic adenocarcinoma is deﬁned as
a mass not directly visible on CT and recognizable only by secondary
imaging signs, when both of the following criteria are fulﬁlled: (a)
CASE  REPORT  –  O
468 K. Blouhos et al. / International Journal of Su
Table 1
Decision/making ﬂow chart of the study patient.
Strong cl inical  suspici on for pancreatobilia ry mali gnancy
Conventional  abdominal  CT
Strong secondary imaging find ings for pancreatic 
head carci noma confirmed al so by dia gnostic  ERC P
Failure to depict  a mass
Dynamic  CT of the pancreas
Failure to depict  a mass
Preoperati ve sta ging:  Suspected mass r esectable 
Excl usion of an isoatt enuat ing mass
Dynamic  MRI  of the pancreas
Failure to depict  a mass
Endo scopic  ultr asou nd, not availa ble
Failure to depict  a mass Depicti on of a  pancreatic  head mass
Isoatte nuati ng mass unmasked
Endoscopic  ultr asou nd guided fine-needle as pirati on
Likel ihood of missed mal ignancy: 6.2%
13
Positi ve cytology for mal ign ancy
Pancreatic oduodenectomy
Negat ive cytology for mal ignancy
Blind pancreaticoduodenectomy
 if strong clinical suspicion for
 pancreatobiliary malignancy persists
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directly visible on CT. In such case, further diagnostic work-upBli nd pancreatic oduodenectomy
o pancreatic lesion of increased or decreased attenuation, com-
ared with the pancreatic parenchyma is observed in both arterial
nd portal phases; (b) no CT ﬁndings of advanced chronic pan-
reatitis or severe obstructive pancreatitis are observed; and (c)
econdary imaging ﬁndings such as interruption or obstruction of
he pancreatic duct or pancreatic parenchymal atrophy, narrowing
n the distal common bile duct, mass effect and/or convex contour
bnormality are present.4
As mentioned above, isoattenuating pancreatic adenocarcinoma
atients represent a small but meaningful subset of patients with
ancreatic cancer. Kim et al., in one of the limited number of studies
hat have been referred in the literature regarding isoattenuating
ancreatic adenocarcinoma patients, showed that these patients
ave a better survival than usual pancreatic adenocarcinoma
atients. In their study, the median survival after curative-intent
urgery was signiﬁcantly longer in visually isoattenuating pan-
reatic adenocarcinoma patients (30 months vs. 15.6 months, = 0.002). The adjusted hazard ratio for visually isoattenuating to
sual pancreatic adenocarcinoma was 0.430, indicating that visu-
lly isoattenuating pancreatic adenocarcinoma was independentlyPEN  ACCESS
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associated with a 57% reduced risk of death after curative-intent
surgery.5 The more favorable postsurgical survival of these patients
makes it even more imperative to correctly diagnose their cases at a
stage when surgical resection is possible, by performing a thorough
diagnostic work-up.
The  reported sensitivity of dynamic multidetector-row CT
(MDCT) in revealing pancreatic carcinoma is high, ranging between
89% and 97%.6 It should be taken into consideration when a sus-
pected pancreatic adenocarcinoma is depicted as isoattenuating
on conventional transverse CT.7 However, considerable limitations
exist, like in our patient’s case, as the frequency of visually isoatten-
uating pancreatic adenocarcinomas on dynamic-enhanced MDCT
among pathologically proved pancreatic cancers has been reported
to range from 5.4% to 14%. Gadolinium-enhanced dynamic MRI
has been reported to be superior to MDCT for depicting: (a) small
lesions; (b) local tumor extent and vascular involvement except
for duodenal invasion and portal venous system involvement;
and (c) isoattenuating masses, as can aid visualization of approxi-
mately 80% of visually isoattenuating pancreatic adenocarcinomas
at CT.8 In our case both dynamic-enhanced CT and MRI  failed to
unmask the mass, which is an extremely rare event. Unfortunately
in our patient’s case endoscopic ultrasound (EUS) was not avail-
able; EUS would have offered us an excellent chance to describe the
sonographic characteristics of an isoattenuating mass, as studies
investigating the utility of EUS for detection of visually isoatten-
uating pancreatic adenocarcinomas could not be recovered in the
literature and may  be worthwhile. Moreover, EUS, if succeeded to
unmask the mass, could have offered us the ability of EUS-guided
ﬁne needle aspiration (FNA) cytology.9 Although a negative result
of EUS-FNA would not have modiﬁed surgical management, a pos-
itive diagnosis would deﬁnitely have supported us to perform a
pancreaticoduodenectomy earlier, on the basis of high speciﬁcity
and a positive predictive value.
When the above imaging studies fail to unmask the mass, many
specialists justify blind pancreaticoduodenectomy (PD) for pan-
creatic head neoplasms with suspected but unproven malignancy,
because: (a) preoperative diagnostic procedures may  complicate
the management or delay surgery, and delaying surgery may
increase the likelihood that a tumor is unresectable or has metas-
tasized; (b) a negative biopsy does not rule out cancer, and biopsy
information does not affect the choice of therapy since a nega-
tive biopsy still commits the patients to surgery; and (c) there is
a low incidence of benign diagnoses after blind PD.10 Indeed, Camp
et al. studied 68 patients who underwent blind PD and found that
61 patients (90%) had a malignant and 7 (10%) had a benign his-
tologically proved diagnosis of chronic inﬂammation/pancreatitis.
The  author concluded that blind PD should be based on com-
bined clinical, CT and/or ERCP data, such in our case.11 In order
to avoid a benign PD, Garcea et al. tried to evaluate the effective-
ness of intraoperative conﬁrmation of malignancy. In their study, 62
patients underwent intraoperative frozen section histology; 6.7% of
them had a missed malignancy, but intraoperative histology pre-
vented PD in 35% of patients with benign disease. However the
author concluded that the chance of missing a small tumor with a
false-negative biopsy will be unacceptable and he would prefer to
undertake a “blind” resection and accept the mortality risk of PD
for benign disease.12
4. Conclusion
Pancreatic adenocarcinomas, when isoattenuating, are notwith dynamic-enhanced pancreatic MDCT, MRI, and EUS should be
obtained, when available, in order to depict a deﬁnitive mass. When
the above studies fail to unmask the lesion, such in our patient case,
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lind PD should be based on strong clinical suspicion and secondary
maging studies.
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